CANTON, Mich. and FRISCO, Texas (August 1, 2019) – MMS Holdings – an award-winning, data-focused CRO – announced that today marks 10 years of successful partnership with Sage IT—a premier provider, helping companies operationalize their vision through the enhancement or development of innovative technology solutions.

CANTON, Mich. (June 27, 2019) – MMS announced today the launch of Automatiqc™ (pronounced: automatic). Automatiqc is a new cloud-based application that automatically performs quality control (QC) and style checks for medical writing, pharmacovigilance, clinical trial transparency, and other types of documents in the pharmaceutical, biotechnology, and medical device industries.

SEATTLE (May 23, 2019) – MMS Holdings Inc. (MMS) – an award-winning, data-focused CRO – announced today the addition of Dr. Mike Poole, MD, FACP to its board of scientific advisors. Currently a venture partner at Biomatics Capital, Inc., Dr. Poole has more than 25 years of experience in the pharmaceutical industry, most recently having led external investments in the Office of the President for Global Health at the Bill and Melinda Gates Foundation.

Staffordshire, United Kingdom (March 13, 2019) – GHP Magazine has awarded MMS Holdings Most Outstanding Global CRO in the 2019 Biotechnology Awards.

by MIT news, January 25, 2019
The timeline to market a new drug or medical device, from the point of discovery to U.S. Food and Drug Administration approval, can stretch to a decade. By pooling its industry experience and technology, a new health research supergroup led by the Julia Lab within the MIT Computer Science and Artificial Intelligence Laboratory aims to significantly shorten the approval process for pharmaceutical and health care groups.

CANTON, Mich. (December 19, 2018) – MMS Holdings Inc. (MMS) – an award-winning, data-focused CRO – announced that the company will host the Michigan SAS Users Group (MSUG) for their first quarter meeting on Wednesday, March 13, 2019.

CANTON, Mich. (November 8, 2018) – MMS Holdings Inc. (MMS) – an award-winning, data-focused CRO – announced that the company has successfully assisted Korea-based Vivozon Inc. in achieving a Fast Track Designation from the Food and Drug Administration (FDA) for VVZ-149, a non-opioid pain killer.

CANTON, Mich. (November 2, 2018) – MMS Holdings Inc. (MMS) – an award-winning, data-focused CRO – announced that one of its leader’s in programming and data sciences, Chris Hurley, has been asked and has accepted a second three-year term as Americas Director of PhUSE – an independent, global organization for more than 8,000 data managers, biostatisticians, clinical programmers, and eClinical IT professionals.

MMS announced today their expert support to Paratek Pharmaceuticals, Inc. for the new drug application (NDA) approval and successful marketing authorisation application (MAA) filing of NUZYRA™ (omadacycline) for…